Zafirlukast.txt

CLINICAL USE

Prophylaxis of asthma

DOSE IN NORMAL RENAL FUNCTION

20 mg twice daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 575.7

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 99

%Excreted unchanged in urine &nbsp &nbsp : 0 (10% as metabolites)

Volume of distribution (L/kg) &nbsp &nbsp &nbsp : 70 litres

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp : 10/Possibly unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function, but use with care

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function, but use with care

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Unlikely to be dialysed. Dose as in normal renal function, but use with care

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Unlikely dialysability. Dose as in normal renal function, but use with care

HDF/high flux &nbsp : Unknown dialysability. Dose as in normal renal function, but use with care

CAV/VVHD &nbsp &nbsp &nbsp: Unknown dialysability. Dose as in normal renal function, but use with care

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Analgesics: concentration increased by aspirin

Antibacterials: concentration reduced by erythromycin

Anticoagulants: may enhance the effects of warfarin Theophylline: zafirlukast possibly increases theophylline concentration; zafirlukast concentration reduced

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Do not take with food as it reduces bioavailability .

Tags: post-by-auto-php